A grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support a two-year preclinical study by Stealth Biotherapeutics to evaluate its investigational therapy SBT-272, a small molecule designed to target cells’ mitochondria. The study is intended to identify biomarkers of mitochondrial dysfunction, a phenomenon often…
Quansys Biosciences and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are teaming up to develop tests that can help monitor Parkinson’s disease progression and evaluate treatment effectiveness in clinical trials. The partnership builds on the company’s expertise in immunoassays, a type of test that uses…
IntelGenx has finalized a research grant agreement with Karolinska University Hospital, Sweden for a placebo-controlled clinical study of Montelukast VersaFilm, an experimental oral thin film formulation for Parkinson’s disease. Manufacturing of both the treatment and its placebo are underway ahead of the study, which will be led by…
Skin cells from people with Parkinson’s disease were transformed into stem cells that could generate dopamine-producing neurons, the same type that’s progressively lost with the disease. The technique opens new avenues for cell therapies to treat Parkinson’s while avoiding possible immune rejections. The researchers used animal models of the…
A sensor chip that can distinguish harmless single units of proteins tied to diseases like Parkinson’s from those whose toxic aggregates are thought to drive disease — including alpha-synuclein — could help in diagnosing conditions before symptoms are evident, when treatments can work best, a study suggests. In addition…
Among available dopamine agonists to treat early Parkinson’s disease, ropinirole is the least likely to cause dyskinesia, the  involuntary movements that can occur from long-term use of these and other Parkinson’s medications, a meta-analysis study suggests. Pramipexole, meanwhile, may be the least likely to cause wearing off…
Gaps in healthcare for individuals with Parkinson’s disease in the U.S. have been identified, with notable disparities observed for women, individuals belonging to minority groups, and residents living in rural areas. That’s according to a study utilizing 2019 Medicare data, which includes approximately 90% of individuals living with Parkinson’s…
The U.S. Food and Drug Administration (FDA) has approved Boston Scientific’s software called Vercise Neural Navigator 5, which provides visual guidance on how to best program deep brain stimulation (DBS) settings for Parkinson’s disease. The improved software features an enhanced user-friendly interface that presents simplified patient data and…
Imaging software developed by Braintale may distinguish Parkinson’s disease from atypical parkinsonism based on measures of early changes in the brain’s white matter, aiding in better diagnoses and disease treatment development. That’s according to initial results from a study into biomarkers on magnetic resonance…
Using a smartwatch to track how fast people can move may help identify who’s at risk for Parkinson’s disease up to seven years before symptoms become evident and doctors make a diagnosis, a study suggests. Wearing the smartwatch for a week was enough to feed an artificial intelligence (AI)-powered…
Get regular updates to your inbox.
